Skip to main content
Erschienen in: Journal of Clinical Immunology 3/2019

29.03.2019 | Original Article

Fatal Enteroviral Encephalitis in a Patient with Common Variable Immunodeficiency Harbouring a Novel Mutation in NFKB2

Erschienen in: Journal of Clinical Immunology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Common variable immunodeficiency is the most prevalent of the primary immunodeficiency diseases, yet its pathogenesis is largely poorly understood. Of the cases that are monogenic, many arise due to pathogenic variants in NFKB1 and NFKB2. Here, we report enteroviral encephalomyelitis as the cause of a fatal neurodegenerative condition in a patient with a novel heterozygous mutation in NFKB2 (c.2543insG, p.P850Sfs36*) that disrupts non-canonical NF-κB signaling. Investigations of primary and secondary lymphoid tissue demonstrated a complete absence of B cells and germinal centers. Despite multiple negative viral PCR testing of cerebrospinal fluid during her disease progression, post-mortem analysis of cerebral tissue revealed a chronic lymphocytic meningoencephalitis, in the presence of Cocksackie A16 virus, as the cause of death. The clinical features, and progression of disease reported here, demonstrate divergent clinical and immunological phenotypes of individuals within a single family. This is the first reported case of fatal enteroviral encephalomyelitis in a patient with NF-κB2 deficiency and mandates a low threshold for early brain biopsy and the administration of increased immunoglobulin replacement in any patient with a defect in this pathway and deterioration of neurological status.
Literatur
1.
Zurück zum Zitat Caamano JH, et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med. 1998;187(2):185–96.CrossRefPubMedPubMedCentral Caamano JH, et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med. 1998;187(2):185–96.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Chen K, Coonrod EM, Kumánovics A, Franks ZF, Durtschi JD, Margraf RL, et al. Germline mutations in NFKB2 implicate the noncanonical NF-kappaB pathway in the pathogenesis of common variable immunodeficiency. Am J Hum Genet. 2013;93(5):812–24.CrossRefPubMedPubMedCentral Chen K, Coonrod EM, Kumánovics A, Franks ZF, Durtschi JD, Margraf RL, et al. Germline mutations in NFKB2 implicate the noncanonical NF-kappaB pathway in the pathogenesis of common variable immunodeficiency. Am J Hum Genet. 2013;93(5):812–24.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lindsley AW, Qian Y, Valencia CA, Shah K, Zhang K, Assa’ad A. Combined immune deficiency in a patient with a novel NFKB2 mutation. J Clin Immunol. 2014;34(8):910–5.CrossRefPubMedPubMedCentral Lindsley AW, Qian Y, Valencia CA, Shah K, Zhang K, Assa’ad A. Combined immune deficiency in a patient with a novel NFKB2 mutation. J Clin Immunol. 2014;34(8):910–5.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Lee CE, Fulcher DA, Whittle B, Chand R, Fewings N, Field M, et al. Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood. 2014;124(19):2964–72.CrossRefPubMedPubMedCentral Lee CE, Fulcher DA, Whittle B, Chand R, Fewings N, Field M, et al. Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood. 2014;124(19):2964–72.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Liu Y, Hanson S, Gurugama P, Jones A, Clark B, Ibrahim MAA. Novel NFKB2 mutation in early-onset CVID. J Clin Immunol. 2014;34(6):686–90.CrossRefPubMed Liu Y, Hanson S, Gurugama P, Jones A, Clark B, Ibrahim MAA. Novel NFKB2 mutation in early-onset CVID. J Clin Immunol. 2014;34(6):686–90.CrossRefPubMed
6.
Zurück zum Zitat Brue T, Quentien MH, Khetchoumian K, Bensa M, Capo-Chichi JM, Delemer B, et al. Mutations in NFKB2 and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies. BMC Med Genet. 2014;15:139.CrossRefPubMedPubMedCentral Brue T, Quentien MH, Khetchoumian K, Bensa M, Capo-Chichi JM, Delemer B, et al. Mutations in NFKB2 and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies. BMC Med Genet. 2014;15:139.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Shi C, Wang F, Tong A, Zhang XQ, Song HM, Liu ZY, et al. NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotropic hormone deficiency. Medicine. 2016;95(40):e5081.CrossRefPubMedPubMedCentral Shi C, Wang F, Tong A, Zhang XQ, Song HM, Liu ZY, et al. NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotropic hormone deficiency. Medicine. 2016;95(40):e5081.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Lougaris V, Tabellini G, Vitali M, Baronio M, Patrizi O, Tampella G, et al. Defective natural killer-cell cytotoxic activity in NFKB2-mutated CVID-like disease. J Allergy Clin Immunol. 2015;135(6):1641–3.CrossRefPubMed Lougaris V, Tabellini G, Vitali M, Baronio M, Patrizi O, Tampella G, et al. Defective natural killer-cell cytotoxic activity in NFKB2-mutated CVID-like disease. J Allergy Clin Immunol. 2015;135(6):1641–3.CrossRefPubMed
9.
Zurück zum Zitat Kuehn HS, Niemela JE, Sreedhara K, Stoddard JL, Grossman J, Wysocki CA, et al. Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype. Blood. 2017;130(13):1553–64.CrossRefPubMedPubMedCentral Kuehn HS, Niemela JE, Sreedhara K, Stoddard JL, Grossman J, Wysocki CA, et al. Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype. Blood. 2017;130(13):1553–64.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Zhu M, Chin RK, Christiansen PA, Lo JC, Liu X, Ware C, et al. NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest. 2006;116(11):2964–71.CrossRefPubMedPubMedCentral Zhu M, Chin RK, Christiansen PA, Lo JC, Liu X, Ware C, et al. NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest. 2006;116(11):2964–71.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Fletcher AL, Seach N, Reiseger JJ, Lowen TE, Hammett MV, Scott HS, et al. Reduced thymic Aire expression and abnormal NF-kappa B2 signaling in a model of systemic autoimmunity. J Immunol. 2009;182(5):2690–9.CrossRefPubMed Fletcher AL, Seach N, Reiseger JJ, Lowen TE, Hammett MV, Scott HS, et al. Reduced thymic Aire expression and abnormal NF-kappa B2 signaling in a model of systemic autoimmunity. J Immunol. 2009;182(5):2690–9.CrossRefPubMed
12.
Zurück zum Zitat Bjorses P, et al. Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet. 1998;7(10):1547–53.CrossRefPubMed Bjorses P, et al. Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet. 1998;7(10):1547–53.CrossRefPubMed
13.
Zurück zum Zitat Ramakrishnan KA, Rae W, Barcenas-Morales G, Gao Y, Pengelly RJ, Patel SV, et al. Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation. J Allergy Clin Immunol. 2018;141(4):1479–1482 e6.CrossRefPubMed Ramakrishnan KA, Rae W, Barcenas-Morales G, Gao Y, Pengelly RJ, Patel SV, et al. Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation. J Allergy Clin Immunol. 2018;141(4):1479–1482 e6.CrossRefPubMed
14.
Zurück zum Zitat Ameratunga R, Koopmans W, Woon ST, Leung E, Lehnert K, Slade CA, et al. Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus. Clin Transl Immunol. 2017;6(10):e159.CrossRef Ameratunga R, Koopmans W, Woon ST, Leung E, Lehnert K, Slade CA, et al. Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus. Clin Transl Immunol. 2017;6(10):e159.CrossRef
15.
Zurück zum Zitat Fliegauf M, L. Bryant V, Frede N, Slade C, Woon ST, Lehnert K, et al. Haploinsufficiency of the NF-kappaB1 subunit p50 in common variable immunodeficiency. Am J Hum Genet. 2015;97(3):389–403.CrossRefPubMedPubMedCentral Fliegauf M, L. Bryant V, Frede N, Slade C, Woon ST, Lehnert K, et al. Haploinsufficiency of the NF-kappaB1 subunit p50 in common variable immunodeficiency. Am J Hum Genet. 2015;97(3):389–403.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Conley ME, Casanova JL. Discovery of single-gene inborn errors of immunity by next generation sequencing. Curr Opin Immunol. 2014;30:17–23.CrossRefPubMed Conley ME, Casanova JL. Discovery of single-gene inborn errors of immunity by next generation sequencing. Curr Opin Immunol. 2014;30:17–23.CrossRefPubMed
18.
Zurück zum Zitat Kaustio M, Haapaniemi E, Göös H, Hautala T, Park G, Syrjänen J, et al. Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes. J Allergy Clin Immunol. 2017;140(3):782–96.CrossRefPubMed Kaustio M, Haapaniemi E, Göös H, Hautala T, Park G, Syrjänen J, et al. Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes. J Allergy Clin Immunol. 2017;140(3):782–96.CrossRefPubMed
19.
Zurück zum Zitat Nagai M, Imai Y, Yamanishi K. Psoriasiform dermatitis associated with common variable immunodeficiency 10 due to an Arg853* mutation in the NFKB2 gene. J Dermatol. 2019;46(1):e24–6.CrossRefPubMed Nagai M, Imai Y, Yamanishi K. Psoriasiform dermatitis associated with common variable immunodeficiency 10 due to an Arg853* mutation in the NFKB2 gene. J Dermatol. 2019;46(1):e24–6.CrossRefPubMed
20.
Zurück zum Zitat Gathmann B, Mahlaoui N, CEREDIH, Gérard L, Oksenhendler E, Warnatz K, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116–26.CrossRefPubMed Gathmann B, Mahlaoui N, CEREDIH, Gérard L, Oksenhendler E, Warnatz K, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116–26.CrossRefPubMed
21.
Zurück zum Zitat Schwab C, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. J Allergy Clin Immunol. 2018;142(6):1932–46. Schwab C, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. J Allergy Clin Immunol. 2018;142(6):1932–46.
22.
Zurück zum Zitat Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014;10(2):360–7.CrossRefPubMed Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014;10(2):360–7.CrossRefPubMed
23.
Zurück zum Zitat Misbah SA, Spickett GP, Ryba PCJ, Hockaday JM, Kroll JS, Sherwood C, et al. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol. 1992;12(4):266–70.CrossRefPubMed Misbah SA, Spickett GP, Ryba PCJ, Hockaday JM, Kroll JS, Sherwood C, et al. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol. 1992;12(4):266–70.CrossRefPubMed
24.
Zurück zum Zitat McKinney RE Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis. 1987;9(2):334–56.CrossRefPubMed McKinney RE Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis. 1987;9(2):334–56.CrossRefPubMed
25.
Zurück zum Zitat Wilfert CM, Buckley RH, Mohanakumar T, Griffith JF, Katz SL, Whisnant JK, et al. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med. 1977;296(26):1485–9.CrossRefPubMed Wilfert CM, Buckley RH, Mohanakumar T, Griffith JF, Katz SL, Whisnant JK, et al. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med. 1977;296(26):1485–9.CrossRefPubMed
26.
Zurück zum Zitat Dendle C, Gilbertson M, Korman TM, Golder V, Morand E, Opat S. Disseminated enteroviral infection associated with obinutuzumab. Emerg Infect Dis. 2015;21(9):1661–3.CrossRefPubMedPubMedCentral Dendle C, Gilbertson M, Korman TM, Golder V, Morand E, Opat S. Disseminated enteroviral infection associated with obinutuzumab. Emerg Infect Dis. 2015;21(9):1661–3.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Palacios T, Bartelt L, Scheld W, Lopes MB, Kelting SM, Holland S, et al. Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy. Ann Allergy Asthma Immunol. 2015;115(2):148–50.CrossRefPubMedPubMedCentral Palacios T, Bartelt L, Scheld W, Lopes MB, Kelting SM, Holland S, et al. Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy. Ann Allergy Asthma Immunol. 2015;115(2):148–50.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat NaserEddin A, Shamriz O, Keller B, Alzyoud RM, Unger S, Fisch P, et al. Enteroviral infection in a patient with BLNK adaptor protein deficiency. J Clin Immunol. 2015;35(4):356–60.CrossRefPubMed NaserEddin A, Shamriz O, Keller B, Alzyoud RM, Unger S, Fisch P, et al. Enteroviral infection in a patient with BLNK adaptor protein deficiency. J Clin Immunol. 2015;35(4):356–60.CrossRefPubMed
29.
Zurück zum Zitat Mantri S, Shah BB. Enterovirus causes rapidly progressive dementia in a 28-year-old immunosuppressed woman. J Neuro-Oncol. 2016;22(4):538–40. Mantri S, Shah BB. Enterovirus causes rapidly progressive dementia in a 28-year-old immunosuppressed woman. J Neuro-Oncol. 2016;22(4):538–40.
31.
Zurück zum Zitat Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28.CrossRefPubMed Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28.CrossRefPubMed
32.
Zurück zum Zitat Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. 2016;4(6):1059–65.CrossRefPubMed Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. 2016;4(6):1059–65.CrossRefPubMed
33.
Zurück zum Zitat Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157(4):669–79.CrossRefPubMed Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157(4):669–79.CrossRefPubMed
34.
Zurück zum Zitat Gofshteyn J, Cardenas AM, Bearden D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurol. 2016;64:94–8.CrossRefPubMed Gofshteyn J, Cardenas AM, Bearden D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurol. 2016;64:94–8.CrossRefPubMed
35.
36.
Zurück zum Zitat Nguyen JT, et al. Neurologic complications of common variable immunodeficiency. J Clin Immunol. 2016;36(8):793–800.CrossRefPubMed Nguyen JT, et al. Neurologic complications of common variable immunodeficiency. J Clin Immunol. 2016;36(8):793–800.CrossRefPubMed
37.
Zurück zum Zitat Akman CI, et al. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev Med Child Neurol. 2009;51(7):563–7.CrossRefPubMed Akman CI, et al. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev Med Child Neurol. 2009;51(7):563–7.CrossRefPubMed
Metadaten
Titel
Fatal Enteroviral Encephalitis in a Patient with Common Variable Immunodeficiency Harbouring a Novel Mutation in NFKB2
Publikationsdatum
29.03.2019
Erschienen in
Journal of Clinical Immunology / Ausgabe 3/2019
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-019-00602-x

Weitere Artikel der Ausgabe 3/2019

Journal of Clinical Immunology 3/2019 Zur Ausgabe

CME Review

CAPS and NLRP3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.